Get the Stockscreener App
2.385
3.03%
+0.075
CureVac N.V. stock is currently priced at $2.385, with a 24-hour trading volume of 60,039.
It has seen a +3.03% increased in the last 24 hours and a -19.05% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.33 pivot point. If it approaches the $2.46 resistance level, significant changes may occur.
Previous Close:
$2.31
Open:
$2.32
24h Volume:
60,039
Market Cap:
$517.26M
Revenue:
$45.82M
Net Income/Loss:
$-319.87M
P/E Ratio:
-1.5246
EPS:
-1.5643
Net Cash Flow:
$-376.79M
1W Performance:
-2.46%
1M Performance:
-19.05%
6M Performance:
-56.01%
1Y Performance:
-67.26%
1D Range:
$2.31
$2.39
52W Range:
$2.215
$12.36
CureVac N.V. Stock (CVAC) Company Profile
Name
CureVac N.V.
Sector
Industry
Phone
49 7 0719 8830
Address
Friedrich-Miescher-Strasse 15, Tübingen
CureVac N.V. Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
CureVac N.V. Stock (CVAC) Latest News
Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
Zacks Investment Research
Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
Zacks Investment Research
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
Benzinga
Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?
Zacks Investment Research
CureVac N.V. Stock (CVAC) Financials Data
CureVac N.V. (CVAC) Revenue 2024
CVAC reported a revenue (TTM) of $45.82 million for the quarter ending September 30, 2023, a -57.28% decline year-over-year.
CureVac N.V. (CVAC) Net Income 2024
CVAC net income (TTM) was -$319.87 million for the quarter ending September 30, 2023, a -149.11% decrease year-over-year.
CureVac N.V. (CVAC) Cash Flow 2024
CVAC recorded a free cash flow (TTM) of -$376.79 million for the quarter ending September 30, 2023, a +34.14% increase year-over-year.
CureVac N.V. (CVAC) Earnings per Share 2024
CVAC earnings per share (TTM) was -$1.552 for the quarter ending September 30, 2023, a -131.02% decline year-over-year.
About CureVac N.V.
CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.
2.32%
0.11%
Cap:
|
Volume (24h):